| pubmed-article:18687447 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18687447 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:18687447 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18687447 | lifeskim:mentions | umls-concept:C0029130 | lld:lifeskim |
| pubmed-article:18687447 | lifeskim:mentions | umls-concept:C0026259 | lld:lifeskim |
| pubmed-article:18687447 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:18687447 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:18687447 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:18687447 | pubmed:dateCreated | 2008-9-1 | lld:pubmed |
| pubmed-article:18687447 | pubmed:abstractText | Mitoxantrone, the first immunosuppressant to receive FDA approval for treatment of worsening relapsing-remitting, secondary progressive, and progressive-relapsing multiple sclerosis (MS) is a DNA topoisomerase II inhibitor that has been associated with the development of acute promyelocytic myelogenous leukemia (APML). Central nervous system APML is a rare site of extramedullary involvement following mitoxantrone therapy. We report a patient with history of multiple sclerosis who developed bilateral optic nerve involvement as the primary manifestation of APML relapse following mitoxantrone treatment. | lld:pubmed |
| pubmed-article:18687447 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18687447 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18687447 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18687447 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18687447 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18687447 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18687447 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:18687447 | pubmed:issn | 0022-510X | lld:pubmed |
| pubmed-article:18687447 | pubmed:author | pubmed-author:VolpeNicholas... | lld:pubmed |
| pubmed-article:18687447 | pubmed:author | pubmed-author:GalettaSteven... | lld:pubmed |
| pubmed-article:18687447 | pubmed:author | pubmed-author:PorterDavidD | lld:pubmed |
| pubmed-article:18687447 | pubmed:author | pubmed-author:McGrathCindyC | lld:pubmed |
| pubmed-article:18687447 | pubmed:author | pubmed-author:TamhankarMadh... | lld:pubmed |
| pubmed-article:18687447 | pubmed:author | pubmed-author:KoMelissa WMW | lld:pubmed |
| pubmed-article:18687447 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18687447 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18687447 | pubmed:volume | 273 | lld:pubmed |
| pubmed-article:18687447 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18687447 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18687447 | pubmed:pagination | 144-7 | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:meshHeading | pubmed-meshheading:18687447... | lld:pubmed |
| pubmed-article:18687447 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18687447 | pubmed:articleTitle | Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. | lld:pubmed |
| pubmed-article:18687447 | pubmed:affiliation | Department of Neurology, State University of New York Upstate Medical University, Syracuse, NY, United States. kom@upstate.edu | lld:pubmed |
| pubmed-article:18687447 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18687447 | pubmed:publicationType | Case Reports | lld:pubmed |
